Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gallbladder disorder09.03.02.0010.002206%Not Available
Gamma-glutamyltransferase increased13.03.01.0110.006619%
Gastric cancer07.21.02.001; 16.13.03.001--Not Available
Gastric haemorrhage07.12.01.001; 24.07.02.007--
Gastric ulcer07.04.03.002--
Gastric ulcer haemorrhage07.04.03.005; 24.07.02.0030.001471%Not Available
Gastritis07.08.02.0010.003677%
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis viral07.19.03.005; 11.05.04.005--Not Available
Gastrointestinal carcinoma07.21.03.001; 16.13.04.0010.000384%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal infection07.19.02.005; 11.01.07.0120.001471%Not Available
Gastrointestinal pain07.01.05.0050.002942%
Generalised oedema08.01.07.004; 14.05.06.0070.004413%
Gingival bleeding07.09.07.001; 24.07.02.010--Not Available
Glucose tolerance impaired05.06.02.001; 14.06.02.0010.002942%
Glycosylated haemoglobin increased13.02.02.0050.002942%Not Available
Gout14.09.01.001; 15.01.06.001--Not Available
Groin pain15.03.02.0040.002206%Not Available
Gynaecomastia05.05.02.003; 21.05.04.003--
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematochezia07.12.02.003; 24.07.02.012--Not Available
Haematuria20.02.01.006; 24.07.01.0470.013974%
Blood urine present13.13.02.0020.012503%Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Haemoptysis02.01.02.006; 22.02.03.004; 24.07.01.006--Not Available
Haemorrhage subcutaneous23.06.07.002; 24.07.06.0100.005148%Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 22 Pages